Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial

JAMA Oncol. 2020 Jun 1;6(6):921-923. doi: 10.1001/jamaoncol.2020.0334.

Abstract

This nonrandomized clinical trial tested [18F]FluorThanatrace as a method for measuring regional poly–(adenosine diphosphate–ribose) polymerase 1 expression in breast cancer and as a potential functional biomarker for breast cancer poly–(adenosine diphosphate–ribose) polymerase inhibitor response.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / metabolism*
  • Female
  • Fluorine Radioisotopes
  • Humans
  • Poly (ADP-Ribose) Polymerase-1 / antagonists & inhibitors
  • Poly (ADP-Ribose) Polymerase-1 / metabolism*
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
  • Positron-Emission Tomography

Substances

  • Fluorine Radioisotopes
  • Poly(ADP-ribose) Polymerase Inhibitors
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1